Abbott India Limited - Asset Resilience Ratio
Abbott India Limited (ABBOTINDIA) has an Asset Resilience Ratio of 53.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Abbott India Limited's Asset Resilience Ratio has changed over time. Check how strategically is Abbott India Limited's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Abbott India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABBOTINDIA market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs12.79 Billion | 22.46% |
| Short-term Investments | Rs17.51 Billion | 30.75% |
| Total Liquid Assets | Rs30.30 Billion | 53.22% |
Asset Resilience Insights
- Very High Liquidity: Abbott India Limited maintains exceptional liquid asset reserves at 53.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abbott India Limited Industry Peers by Asset Resilience Ratio
Compare Abbott India Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Abbott India Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Abbott India Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 51.26% | Rs30.33 Billion ≈ $328.01 Million |
Rs59.17 Billion ≈ $639.93 Million |
+12.66pp |
| 2024-03-31 | 38.59% | Rs20.04 Billion ≈ $216.75 Million |
Rs51.93 Billion ≈ $561.66 Million |
-2.24pp |
| 2023-03-31 | 40.83% | Rs18.60 Billion ≈ $201.18 Million |
Rs45.56 Billion ≈ $492.66 Million |
-22.31pp |
| 2022-03-31 | 63.15% | Rs26.67 Billion ≈ $288.48 Million |
Rs42.24 Billion ≈ $456.82 Million |
+2.00pp |
| 2020-03-31 | 61.14% | Rs21.69 Billion ≈ $234.53 Million |
Rs35.47 Billion ≈ $383.58 Million |
+7.69pp |
| 2019-03-31 | 53.46% | Rs15.72 Billion ≈ $170.01 Million |
Rs29.41 Billion ≈ $318.05 Million |
+12.59pp |
| 2018-03-31 | 40.86% | Rs9.87 Billion ≈ $106.78 Million |
Rs24.16 Billion ≈ $261.30 Million |
-11.65pp |
| 2017-03-31 | 52.51% | Rs10.85 Billion ≈ $117.32 Million |
Rs20.66 Billion ≈ $223.41 Million |
+9.48pp |
| 2016-03-31 | 43.03% | Rs6.96 Billion ≈ $75.23 Million |
Rs16.17 Billion ≈ $174.82 Million |
-0.04pp |
| 2015-03-31 | 43.07% | Rs5.92 Billion ≈ $63.99 Million |
Rs13.74 Billion ≈ $148.55 Million |
+19.96pp |
| 2013-03-31 | 23.11% | Rs2.10 Billion ≈ $22.67 Million |
Rs9.07 Billion ≈ $98.10 Million |
+4.93pp |
| 2012-03-31 | 18.18% | Rs1.46 Billion ≈ $15.74 Million |
Rs8.00 Billion ≈ $86.54 Million |
+13.97pp |
| 2011-03-31 | 4.22% | Rs192.81 Million ≈ $2.09 Million |
Rs4.57 Billion ≈ $49.46 Million |
+0.06pp |
| 2010-03-31 | 4.15% | Rs161.22 Million ≈ $1.74 Million |
Rs3.88 Billion ≈ $41.97 Million |
+0.97pp |
| 2009-03-31 | 3.19% | Rs111.80 Million ≈ $1.21 Million |
Rs3.51 Billion ≈ $37.91 Million |
-0.05pp |
| 2008-03-31 | 3.24% | Rs107.00 Million ≈ $1.16 Million |
Rs3.30 Billion ≈ $35.73 Million |
-0.53pp |
| 2007-03-31 | 3.77% | Rs128.30 Million ≈ $1.39 Million |
Rs3.40 Billion ≈ $36.82 Million |
-0.20pp |
| 2006-03-31 | 3.97% | Rs123.30 Million ≈ $1.33 Million |
Rs3.10 Billion ≈ $33.57 Million |
+1.77pp |
| 2005-03-31 | 2.21% | Rs68.90 Million ≈ $745.13K |
Rs3.12 Billion ≈ $33.75 Million |
-- |
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, … Read more